Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...